What drove the growth in Royalty Receipts in the first quarter of 2025?

Royalty Receipts grew 12% to $788 million, primarily due to strong performance from the cystic fibrosis franchise, Trelegy and Xtandi, as well as royalties from the 2024 launch of Voranigo. Portfolio Receipts grew 17% to $839 million, also helped by a $27 million milestone payment related to Airsupra.

Why did operating cash flow decline even as Portfolio Receipts grew?

Net cash provided by operating activities was $596 million versus $665 million in Q1 2024. Interest paid rose to $139 million from $79 million, payments for operating and professional costs rose to $102 million from $61 million, and development-stage funding payments were $51 million. Payments for operating and professional costs included a $33 million one-time management fee related to the sale of the MorphoSys Development Funding Bonds.

How much did Royalty Pharma spend on share repurchases, and what is left under the authorization?

The company repurchased about 23 million Class A ordinary shares for $723 million in Q1 2025 under a $3.0 billion authorization announced in January 2025. The filing states that weighted-average diluted Class A ordinary shares outstanding were 578 million in Q1 2025, compared with 597 million in Q1 2024.

What are the terms of the internalization transaction and when is it expected to close?

The total transaction value is approximately $1.1 billion, consisting of about 24.5 million Royalty Pharma shares vesting over five to nine years, approximately $100 million in cash, and the assumption of $380 million of the Manager's existing debt. Closing requires shareholder approval of the share issuance on May 12, 2025, and is expected in the second quarter of 2025. Cash savings are expected to exceed $100 million in 2026 and $175 million in 2030.

What is the updated 2025 financial outlook?

Portfolio Receipts guidance was raised to $2,975 million to $3,125 million, from $2,900 million to $3,050 million. Payments for operating and professional costs are expected to be approximately 10% of Portfolio Receipts, and interest paid is expected to be $260 million, both unchanged. Guidance excludes new transactions announced after the release date and will be updated for costs and interest after the internalization closes.

RPRX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 8, 2025. Cited figures are marked; the original filing is the authoritative source.

Royalty Pharma plc reported first-quarter 2025 results for the quarter ended March 31, 2025, with Portfolio Receipts up 17% to $839 million^a and Royalty Receipts up 12% to $788 million.

Growth was driven mainly by the cystic fibrosis franchise, Trelegy and Xtandi, plus royalties from the 2024 launch of Voranigo and a $27 million^b Airsupra milestone. Net cash provided by operating activities was $596 million, down from $665 million a year earlier, reflecting higher interest paid and a $33 million one-time management fee tied to the MorphoSys Development Funding Bonds sale. Adjusted EBITDA rose 12% to $738 million and Portfolio Cash Flow rose 5% to $611 million.

Net income attributable to Royalty Pharma plc was $238 million^c. Capital allocation was active. The company repurchased about 23 million Class A ordinary shares for $723 million under a new $3.0 billion authorization, and it raised full-year 2025 Portfolio Receipts guidance to $2,975 million to $3,125 million, up from $2,900 million to $3,050 million.

It also entered a Biogen R&D funding arrangement for litifilimab worth up to $250 million^d over six quarters, and it increased its quarterly dividend by approximately 5%. Cash and cash equivalents were $1.1 billion and total debt principal was $7.8 billion at March 31, 2025. The internalization of its external manager, RP Management, LLC, is expected to close in the second quarter of 2025, following a shareholder meeting on May 12, 2025.

The total transaction value is approximately $1.1 billion, consisting of about 24.5 million shares vesting over five to nine years, about $100 million in cash, and the assumption of $380 million of the Manager's debt. The company expects cash savings of greater than $100 million in 2026, rising to greater than $175 million in 2030. Guidance for operating and professional costs and interest paid will be updated after the closing.

02—Key points

Key Highlights

Portfolio Receipts rose 17% to $839 million in Q1 2025, and Royalty Receipts rose 12% to $788 million.
Net cash provided by operating activities was $596 million, compared with $665 million in Q1 2024, a decline of (10)%.
Adjusted EBITDA (non-GAAP) increased 12% to $738 million, and Portfolio Cash Flow (non-GAAP) increased 5% to $611 million.
Repurchased about 23 million Class A ordinary shares for $723 million under a new $3.0 billion authorization.
Raised full-year 2025 Portfolio Receipts guidance to $2,975 million to $3,125 million, from $2,900 million to $3,050 million, representing expected growth of 6% to 12%.
Internalization of the external manager, RP Management, LLC, has a total transaction value of approximately $1.1 billion and is expected to close in Q2 2025, with cash savings of greater than $100 million in 2026.
Ended the quarter with $1.1 billion in cash and cash equivalents and $7.8 billion of total debt principal.

03—Questions

Frequently Asked Questions

What drove the growth in Royalty Receipts in the first quarter of 2025?
Royalty Receipts grew 12% to $788 million, primarily due to strong performance from the cystic fibrosis franchise, Trelegy and Xtandi, as well as royalties from the 2024 launch of Voranigo. Portfolio Receipts grew 17% to $839 million, also helped by a $27 million milestone payment related to Airsupra.
Why did operating cash flow decline even as Portfolio Receipts grew?
Net cash provided by operating activities was $596 million versus $665 million in Q1 2024. Interest paid rose to $139 million from $79 million, payments for operating and professional costs rose to $102 million from $61 million, and development-stage funding payments were $51 million. Payments for operating and professional costs included a $33 million one-time management fee related to the sale of the MorphoSys Development Funding Bonds.
How much did Royalty Pharma spend on share repurchases, and what is left under the authorization?
The company repurchased about 23 million Class A ordinary shares for $723 million in Q1 2025 under a $3.0 billion authorization announced in January 2025. The filing states that weighted-average diluted Class A ordinary shares outstanding were 578 million in Q1 2025, compared with 597 million in Q1 2024.
What are the terms of the internalization transaction and when is it expected to close?
The total transaction value is approximately $1.1 billion, consisting of about 24.5 million Royalty Pharma shares vesting over five to nine years, approximately $100 million in cash, and the assumption of $380 million of the Manager's existing debt. Closing requires shareholder approval of the share issuance on May 12, 2025, and is expected in the second quarter of 2025. Cash savings are expected to exceed $100 million in 2026 and $175 million in 2030.
What is the updated 2025 financial outlook?
Portfolio Receipts guidance was raised to $2,975 million to $3,125 million, from $2,900 million to $3,050 million. Payments for operating and professional costs are expected to be approximately 10% of Portfolio Receipts, and interest paid is expected to be $260 million, both unchanged. Guidance excludes new transactions announced after the release date and will be updated for costs and interest after the internalization closes.

04—Continue

← View all 8-K filings